Diagnosis and Management of Lymphoma

Mantle Cell Lymphoma: Decision Making for Transplant

“…Recently, bortezomib [61][62][63] , lenalidomide [64][65][66] , bendamustine [67][68][69] , pixantrone 70 , azaepothilone ixabepilone 71 and mTOR inhibitor temsirolimus [72][73][74] has been shown to demonstrate activity alone and in combination with rituximab and mitoxantrone, and may induce complete responses in relapsed or refractory MCL 61,64,69,75,76 . Along with rituximab, these biotherapy agents can be used frontline or may also be introduced into post transplant maintenance to prevent or treat relapses 61,68,[77][78][79][80][81] .…”